SYNEURX
Live / Registered — Registered — partial Section 8 accepted (as of 02 Oct 2024)
What this means for you
Registered since 06 Mar 2018. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 87090968
- Registration number
- 5419035
- Mark type
- Stylized text
- Filed
- 01 Jul 2016
- Published for opposition
- 23 May 2017
- Registered
- 06 Mar 2018
- Attorney of record
- Paul Cosmovici
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical products and substances for treating neuropsychiatric disorders, namely, schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia, bipolar disorder, and other central nervous system disorders; medicines for neuropsychiatric disorders, namely, schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia, bipolar disorder, and other central nervous system disorders; pharmaceutical preparations for neuropsychiatric disorders, namely, schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia, bipolar disorder, and other central nervous system disorders; sodium salts for medical purposes
- Class 042 — Scientific and technological services: [ Pharmaceutical preparations and drug development services for developing drugs for treating neuropsychiatric disorders, namely, schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia, bipolar disorder, and other central nervous system disorders; Biological research; Clinical lab test of medical reagents for conducting clinical trials for others in the field of neuropsychiatric disorders, namely, schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia, bipolar disorder, and other central nervous system disorders; Scientific research and analysis in the field of medical reagents; Providing research and development of technology in the field of neuropsychiatric disorders, namely, schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia, bipolar disorder, and other central nervous system disorders; Technical research in the field of neuropsychiatric disorders, namely, schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia, bipolar disorder, and other central nervous system disorders; Technical project studies in the field of neuropsychiatric disorders, namely, schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia, bipolar disorder, and other central nervous system disorders; Scientific laboratory services ]
Owner
- SyneuRx International Corp., Taipei City 110, TW
- SyneuRx International Corp., Taipei City 110, TW
- SyneuRx International Corp., Taipei City 110, TW
Prosecution history
- 07 May 2025 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 07 May 2025 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
- 07 May 2025 — TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
- 02 Oct 2024 — NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED
- 02 Oct 2024 — REGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED
- 25 Sept 2024 — CASE ASSIGNED TO POST REGISTRATION PARALEGAL
- 21 Feb 2024 — TEAS SECTION 8 RECEIVED
- 06 Mar 2023 — COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
- 25 Jan 2023 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 25 Jan 2023 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
- 25 Jan 2023 — TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
- 06 Mar 2018 — REGISTERED-PRINCIPAL REGISTER
- 31 Jan 2018 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 30 Jan 2018 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 30 Jan 2018 — STATEMENT OF USE PROCESSING COMPLETE